Evidence map›Paper›PMID 26096933›Full record

ArticleOncogene2016

Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents.

W-B Tsai, Y Long, J-R Park, J T Chang, H Liu, J Rodriguez-Canales, N Savaraj, L G Feun, M A Davies, I I Wistuba and 1 more

Abstract read
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

W-B TsaiDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y LongDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J-R ParkDepartment of Thoracic and Cardiovascular Surgery, Kangwon National University, Gangwon, Korea.
J T ChangDepartment of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, TX, USA.
H LiuDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Rodriguez-CanalesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
N SavarajSylvester Comprehensive Cancer Center, University of Miami, VA Medical Center, Miami, FL, USA.
L G FeunSylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
M A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
I I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M T KuoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USSylvester Comprehensive Cancer Center · USKangwon National University · KRThe University of Texas Health Science Center at Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Improving the Efficacy of Cisplatin-Based Cancer ChemotherapyR01CA149260 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KUO, MACUS T · 2010 to 2014
$1.6M
Mechanism of Resistance to Arginine Deiminase Therapy in Advance MelanomaR01CA152197 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KUO, MACUS T · 2010 to 2013
$1.3M
Overcoming BRAF and MEK Inhibitors Resistance in Advanced MelanomaI01BX003328 · VA · MIAMI VA HEALTH CARE SYSTEM · PI SAVARAJ, NIRAMOL · 2016 to 2019
–
BLRD VA I01 BX003328NCI NIH HHS P30 CA016672NCI NIH HHS P30CA16672NCI NIH HHS R01 CA149260NCI NIH HHS R01 CA152197
6 · The paper itself

Abstract

Many human malignancies lack de novo biosynthesis of arginine (Arg) as the key enzyme argininosuccinate synthetase 1 (ASS1) is silenced. These tumors acquire ectopic Arg for survival, and depleting this source by Arg-depleting recombinant enzyme ADI-PEG20 results in cell death. Mechanisms underlying Arg auxotrophy in these tumors and how they respond to Arg-auxotrophic stress are poorly understood. Here, we report that an immediate-early event of Arg-auxotrophic response involves reactive oxygen species-mediated secretion of Gas6, which interacts with its receptor Axl and activates the downstream Ras/PI3K/Akt growth signal leading to accumulation of c-Myc by protein stabilization. Arg-auxotrophic challenge also transcriptionally upregulates c-Myc expression, which provides a feedback mechanism to enhance Axl expression. c-Myc is a positive regulator of ASS1, but elevated ASS1 provides a feedback mechanism to suppress c-Myc and Axl. Our results revealed multiple inter-regulatory pathways in Arg-auxotrophic response, consisting of Axl, c-Myc and ASS1, which regulate Arg homeostasis and ADI-PEG20 sensitivity. These pathways provide potential targets for improving the efficacy of treating Arg-auxotrophic tumors using Arg-deprivation strategies.

Indexed as

Antineoplastic AgentsArginineAxl Receptor Tyrosine KinaseCell DeathCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGrowth Arrest-Specific Protein 6HumansHydrolasesIntercellular Signaling Peptides and ProteinsMolecular Targeted TherapyNeoplasmsPolyethylene GlycolsProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesADI PEG20Antineoplastic AgentsArginineAXL protein, humanAxl Receptor Tyrosine KinaseGrowth Arrest-Specific Protein 6HydrolasesIntercellular Signaling Peptides and ProteinsPolyethylene GlycolsProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinases

Identifiers

PMID26096933
PMCPMC4835044
OpenAlexW1490487906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.